Living With Asthma?
If you are living with asthma and seeking new treatment options, you may qualify for a clinical trial evaluating investigational medications.
Gain access to study-related care from a local medical team, receive potential new treatments at no cost, and get compensated for your time and travel.
Why Participate in Research?
Try Potential New Ways to Stay Healthy
You may receive access to a study medication being evaluated for asthma, with regular check-ins from a dedicated healthcare team.
Help Make a Difference
Play an important role in research that may improve future prevention and treatment options for communities and loved ones.
Compensation for Participation
Receive compensation for your time and involvement, which may include study visits, follow-ups, or providing health information.
About the Study
This research study is testing a new asthma medication to see how well it works compared to an approved treatment. Researchers will also closely monitor safety and how the medication is tolerated.
What to Expect
The study lasts about 9–10 weeks and includes 4 clinic visits and 5 phone check-ins. You will use a once-daily inhaled study medication and be monitored by a healthcare team throughout.
Why Participate
If you qualify, you may receive study-related medical care, access to the study medication, and compensation for your time and travel. You’ll also be helping support the future of asthma treatment.
Who May Qualify
You may be eligible if you:
-
Are 18–75 years old
-
Have been diagnosed with asthma
-
Are currently on a stable asthma treatment plan
-
Are a non-smoker (or light former smoker)
form here
Get In Touch
Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere.
Divi Investment Firm.
Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a Cras ultricies ligula sed magna dictum porta.